Biosolution Co., Ltd. has been established in January 14th, 2000 on a motive to lead the market in manufacturing and selling cell therapy products, and to pursue development in cell therapeutics technology. The main areas of our leading business include cell based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with our tissue engineering technology.

Biosolution Co., Ltd. received product approval for KeraHeal, a sprayable autologous keratinocyte medication for severe burns, in 2006 and approval for coverage under the occupational health and safety insurance in 2009. We also have received product approval for KeraHeal-Allo, an allogeneic keratinocyte therapy product in the form of hydrogel, in October, 2015. Biosolution Co., Ltd. is also under phase 2 clinical trials for CartiLife, a small spherical autologous chondrocyte therapy product used to cure arthritis.

The human tissue models are sold for the assessment of the toxicity and efficacy of cosmeceutics and drugs on the human body which fall under our contracted research services category. Furthermore, we are performing research led by the Korea Food & Drug Administration on our human tissue models for registration on the OECD test guidelines as a standard model for alternatives to animal testing; documents are planned for submission within this year. We are currently selling SteM水(SteMSoo), a media extract comprised of human stem cells that possess anti-wrinkle effects, whitening effects, and recovery in the elasticity of the skin.

Read more…